Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

50.01USD
24 Jun 2016
Change (% chg)

$-1.36 (-2.65%)
Prev Close
$51.37
Open
$50.10
Day's High
$51.30
Day's Low
$49.99
Volume
1,202,259
Avg. Vol
1,114,399
52-wk High
$72.31
52-wk Low
$49.51

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $52,407.62
Shares Outstanding(Mil.): 1,022.26
Dividend: 0.34
Yield (%): 2.72

Financials

  TEVA.N Industry Sector
P/E (TTM): 26.04 33.11 34.49
EPS (TTM): 1.92 -- --
ROI: 4.98 14.75 14.01
ROE: 6.40 15.86 15.24

BRIEF-Teva Pharmaceutical gets CHMP positive opinion for Cinqaero

* Final decision by European Commission is expected in second half of 2016

24 Jun 2016

Deals of the day-Mergers and acquisitions

June 21 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

22 Jun 2016

Impax buys generic drugs from Teva, Allergan for $586 million

Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

21 Jun 2016

UPDATE 1-Impax buys generic drugs from Teva, Allergan for $586 mln

June 21 Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

21 Jun 2016

BRIEF-Impax signs agreements to acquire generic products from Teva, Allergan

* Expects 2016 total company revenues to increase at least 15% over full year 2015

21 Jun 2016

Impax buys portfolio of generic products from Teva, Allergan

June 21 Impax Laboratories Inc said it would buy a portfolio of generic products from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

21 Jun 2016

UPDATE 1-Mesoblast shares slump to 2009 low as Teva ends partnership

* Mesoblast shares plummet 42 pct to lows not seen since 2009

14 Jun 2016

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

14 Jun 2016

Mesoblast regains full rights to stem cell heart failure treatment

June 13 Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

14 Jun 2016

Deals of the day- Mergers and acquisitions

June 13 The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday:

13 Jun 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.75 -1.20
Biogen Inc (BIIB.OQ) $229.02 -9.60

Earnings vs. Estimates